These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 21083760)

  • 1. Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
    Willcox MD
    Clin Exp Optom; 2011 Mar; 94(2):161-8. PubMed ID: 21083760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin-resistant Pseudomonas keratitis.
    Garg P; Sharma S; Rao GN
    Ophthalmology; 1999 Jul; 106(7):1319-23. PubMed ID: 10406614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy.
    Sharma V; Sharma S; Garg P; Rao GN
    Indian J Ophthalmol; 2004 Dec; 52(4):287-92. PubMed ID: 15693319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
    Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
    Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals.
    Rogues AM; Dumartin C; Amadéo B; Venier AG; Marty N; Parneix P; Gachie JP
    Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1389-95. PubMed ID: 17994520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
    Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
    Engel LS; Callegan MC; Hill JM; Folkens AT; Shimomura Y; O'Callaghan RJ
    Jpn J Ophthalmol; 1996; 40(2):212-9. PubMed ID: 8876389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
    Aliprandis E; Ciralsky J; Lai H; Herling I; Katz HR
    Cornea; 2005 Mar; 24(2):201-5. PubMed ID: 15725889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.
    Mannis MJ
    Trans Am Ophthalmol Soc; 2002; 100():243-71. PubMed ID: 12545697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
    Khan M; Ma K; Wan I; Willcox MD
    Cont Lens Anterior Eye; 2023 Jun; 46(3):101819. PubMed ID: 36732125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of combined gentamicin-corticosteroid treatment on gentamicin-resistant Pseudomonas keratitis.
    Stern GA; Okumoto M; Friedlaender M; Smolin G
    Ann Ophthalmol; 1980 Sep; 12(9):1011-4. PubMed ID: 6821445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year analysis of microbiological profile and antibiotic sensitivity for bacterial keratitis in Korea.
    Mun Y; Kim MK; Oh JY
    PLoS One; 2019; 14(3):e0213103. PubMed ID: 30822325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
    Hyatt JM; Schentag JJ
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S9-11. PubMed ID: 10654629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
    Lauffenburger MD; Cohen KL
    Cornea; 1993 Nov; 12(6):517-21. PubMed ID: 8261784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection.
    Oo TZ; Cole N; Garthwaite L; Willcox MD; Zhu H
    J Antimicrob Chemother; 2010 Jun; 65(6):1243-51. PubMed ID: 20375033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.